Evidence-Based Practice (EBP): Why has EBP emerged?

Dept. of Radiography. Meduns. South Africa.
Ogunbanjo GA, MBS, MFGP (SA), M Fam Med, FACRRM, FACTM
Dept. of Family Medicine and Primary Health Care. Meduns. South Africa
Correspondence: Mrs N Ebrahim: nebraham@meduns.a.ca.za
Prof GA Ogunbanjo: gbobyega@intekom.co.za
Keywords: evidence-based medicine, practice, healthcare, primary care, education

Introduction

This article aims to inform the family practitioner why EBP emerged. (SA Fam Pract 2003;45(9): 47-48)

WHY HAS EVIDENCE-BASED PRACTICE EMERGED?

"Evidence-based practice is the acknowledgement of uncertainty followed by the seeking, appraising and implementation of new knowledge". It enables practitioners to openly accept other and possibly more effective methods of care than those currently employed. This approach is appealing to the new researcher or to the researcher who is willing to change. The following factors contributed to the emergence of EBP.

THE RESEARCH-PRACTICE GAP

According to Upton D et al, in the case of medicine and professions allied to medicine, there is a limited extent to which professions utilise research findings to guide their actions. Professionals depend traditionally on a range of other indicators such as, knowledge gained during primary training; prejudice and opinion; outcomes of previous cases; fads and fashions; advice from colleagues.

THE QUALITY OF PUBLISHED RESEARCH

It is argued that much of the research available is methodologically weak because it is not based on the ‘gold standard’ of well-conducted random clinical trial designs or is inapplicable with clinical situations. This argument is made by exponents of evidence-based medicine and supported by those attached to evidence-based health professionals. However, whilst the systematic review of several randomised trials is more likely to inform us, it has become the ‘gold standard’ for finding whether a treatment does more good than harm.

INFORMATION OVERLOAD

"The amount of research available creates problems itself". The number of journal publications, the increase in post-graduate presentations, the introduction of continuing professional development have prompted the development of skills for finding relevant research in order to keep up with global trends.

PRACTICE THAT IS NOT EVIDENCE-BASED

Current approaches to practice relying only on experience and information overload has promulgated the continuance of practice that is not evidence-based. The emergence of evidence-based practice has provided a 'tailor made solution to these problems and one which has been readily adopted throughout the health profession and beyond'.

THE RISK SOCIETY

The first major influence on EBP is that we live in changing times. The degree of change is influenced by awareness of risk. EBP has also emerged within the context where there is a heightened sense of risk. Thus increasing reliance upon as well as increased distrust in expertise. Printed and electronic media have contributed to increasing public awareness. Formulation and publication of various ‘patient rights’ documents empower clients to question our actions. EBP remains committed to the modernist promise that risk can be assessed and controlled.

MANAGERIAL AND AUDIT SOCIETY

Another major influence has been the significant changes in managerialism. The emphasis on value for money and growth of audits has contributed to shaping the goals for EBP. This, together with the awareness of risk, has over the last two decades witnessed the changes in organizations and public services. In the academic setting, heads of departments are required not just to ‘run a department’ but also need to manage departments. Auditing systems have been developed where value-for-
money can be measured. These systems are primarily economy, efficiency and effectiveness. These issues will be addressed later in the series. According to Dawes, EBP "is not an academic exercise". Trinder reports that, "the core of evidence-based practice is its procedure rather than substantive output," whilst some of the reasons for the emergence of evidence-based medicine and evidence-based health care are cited, the overlap between the managerial and evidence-based practice agenda was as a result of changes in public services. The focus on performance and effectiveness is dispersed throughout organisations and not confined to management. EBP takes a democratic approach and years of experience are not necessarily the yardstick by which professionals are judged. The most junior member of a profession can be skilled in identifying evidence. EBP has developed within a specific context in line with current thoughts concerning risk, professional expertise and the needs of the consumer. Its success can be attributed to its ability to endorse and redefine some of these concerns.

**References**


Hexal Pharma (S.A) announces ZolpiHexal 10mg

Hexal Pharma (S.A) takes pride in announcing the launch of ZolpiHexal 10mg as the latest addition to our comprehensive product portfolio. ZolpiHexal 10mg contains zolpidem tartrate 10mg as the active ingredient and is registered as bioequivalent to the originator brand. Naturally, ZolpiHexal 10mg enjoys international status, and is yet another quality German generic sourced from Hexal AG. ZolpiHexal 10mg displays highly favourable pharmacokinetics viz bioavailability of almost 70% and peak plasma concentrations between 0.5 and 3 hours after dosing.

ZolpiHexal 10mg is indicated for the short term treatment of insomnia. The recommended daily dose for adults is 10mg immediately before bedtime ZolpiHexal 10mg enters the market at a R.R.P. which is almost 50% more cost-effective versus the originator brand.

Further product-related information on ZolpiHexal 10mg or other Hexal generic's available from Nic Shelver: Tel: (031) 700 6801 or e-mail: nshelver@hexal.co.za.

Hexal Pharma (S.A) announces CIPRO-HEXAL 250/500/750mg

Hexal Pharma(S.A.) is proud to announce the launch of CIPRO-HEXAL 250/500/750 mg, film-coated tablets(250mg ciprofloxacin,500mg ciprofloxacin,750mg ciprofloxacin,respectively). Cipro-Hexal 250/500/750 mg is an international Hexal brand and is sourced from the international HEXAL AG pipeline.Cipro-Hexal 250/500/750 mg is bactericidal versus both certain Gram-positive and Gram-negative organisms.

Indications include the treatment of lower respiratory tract infections, urinary tract infections, skin and soft tissue infections,gastro-intestinal infections, bone infections and gonorrhoea. Cipro-Hexal 250/500/750 immediately adds value to the comprehensive antibiotic line-up from Hexal Pharma(SA.) and will be available from traditional pharmaceutical distribution outlets.

Further product-related information on ZolpiHexal 10mg or other Hexal generic's available from Nic Shelver: Tel: (031) 700 6801 or e-mail: nshelver@hexal.co.za.